Novo Nordisk is expanding its collaboration with the U.S.-based technology company, Valo Health. This partnership aims to accelerate the development of new treatments for obesity, cardiovascular ...

Novo Nordisk is planning to open an artificial ... In September, for example, the company signed an agreement with US start-up Valo Health to apply its AI-powered drug discovery engine to find ...

Novo Nordisk almost doubles the scale of its R&D alliance with AI specialist Valo Health, which now spans 20 programmes and a value of up to $4.6bn. Artificial intelligence (AI) has long promised ...

Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk (NVO) was slammed by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results ...

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

This page features the latest news about the Novo Nordisk B stock. Deutsche Bank cuts Novo Nordisk stock target, keeps Buy rating on Q3 results On Thursday, an analyst from Deutsche Bank (ETR ...

Novo Nordisk's (CO:NOVOb) top-selling diabetes drug Victoza cut the risk of heart attack, stroke and cardiovascular death by 13 percent in a... Investing.com – Denmark stocks were lower after ...